Revenue for the quarter saw a 15.8% year-on-year uptick to ₹3,770.5 crore, up from ₹3,256.2 crore. On the gross unit front, EBITDA escalated by 35.9% to ₹762.5 crore, in contrast to ₹561.1 crore previously. The EBITDA margin grew to 20.2%, compared to 17.2% during the same quarter last year.
The company recorded consolidated revenue of ₹16,982.5 crore for FY26, marking a year-on-year growth of 27.5%.
EBITDA for FY26 reached ₹4,572.4 crore, with an EBITDA margin of 26.9%. Profit after tax (PAT) for FY26 amounted to ₹1,362 crore, achieving a PAT margin of 7.8%.
In FY26, IGI secured a licensing agreement with AbbVie for ISB 2001, developed through IGI’s proprietary BEAT protein platform for oncology and autoimmune diseases.
ALSO READ | Glenmark’s US arm settles generic drug pricing case for $29.6 million
The agreement includes an upfront payment of $700 million, with a potential total deal value of $1.925 billion and tiered double-digit royalties on net sales. Glenmark will lead commercialization efforts across emerging markets.
During FY26, Glenmark also expanded its oncology business in India and emerging markets by in-licensing commercial rights for Trastuzumab Rezetecan from Hengrui Pharma and Aumolertinib from Hansoh Pharma.
The company noted that its India business grew at 1.5 times the growth rate of the Indian Pharmaceutical Market (IPM) in secondary sales and ranked as the second fastest-growing company among the top 15 firms in FY26, according to IQVIA.
Differentiated product launches during FY26 included TEVIMBRA and BRUKINSA in oncology, Nebzmart GFB Smartules and Glenmark Airz FB Smartules in respiratory therapies, and GLIPIQ in diabetes.
Glenmark Pharmaceuticals has announced that its board has approved the transfer of the company’s nebuliser brands/IP portfolio to Glenmark Healthcare Ltd (GHL), a wholly owned subsidiary of the company.
Also Read: Glenmark Pharma Q1 Results | Net profit plunges 86% to ₹47 crore despite stable revenue
This transfer is anticipated to occur at a cash consideration of ₹223 crore based on an independent valuation report. The agreement for the transfer is set to be executed on June 1, 2026, and is expected to be finalized by June 30, 2026.
For the nine months ending December 31, 2025, the nebuliser business generated revenue of ₹71.6 crore, accounting for about 1.3% of the company’s standalone revenue for that period. The net worth of the GHL business was reported at negative ₹9.9 crore as of March 31, 2026.
Glenmark Healthcare Ltd specializes in manufacturing pharmaceutical products, and this transaction qualifies as a related party transaction conducted at arm’s length. There will be no alteration in the shareholding structure of Glenmark Pharmaceuticals following the transfer.
The company indicated that the nebuliser business segment is seeing growth in India and emerging markets, with the transfer aimed at enabling greater strategic focus and operational agility. GHL is also establishing a dedicated nebuliser manufacturing facility and will manage an array of innovative nebulisers, including a nebulised triple therapy for Chronic Obstructive Pulmonary Disease (COPD).
The company has also proposed a dividend of 250%, equating to ₹2.5 per equity share of face value ₹1 each, for FY26. This dividend is subject to approval by shareholders at the upcoming annual general meeting.
Also Read: Glenmark Pharma guides for 23% core margins in FY27
On May 29, shares of Glenmark Pharmaceuticals Ltd closed at ₹2,274.25, down by ₹108.40, or 4.55%, on the BSE.
